KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Issued (2017 - 2025)

Amneal Pharmaceuticals has reported Shares Issued over the past 9 years, most recently at $553000.0 for Q4 2025.

  • Quarterly results put Shares Issued at $553000.0 for Q4 2025, up 266.23% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 69.84% YoY), and the annual figure for FY2025 was $2.0 million, up 69.84%.
  • Shares Issued for Q4 2025 was $553000.0 at Amneal Pharmaceuticals, down from $653000.0 in the prior quarter.
  • Over the last five years, Shares Issued for AMRX hit a ceiling of $685000.0 in Q2 2025 and a floor of $5000.0 in Q2 2021.
  • Median Shares Issued over the past 5 years was $153000.0 (2021), compared with a mean of $298823.5.
  • Peak annual rise in Shares Issued hit 13420.0% in 2021, while the deepest fall reached 96.73% in 2021.
  • Amneal Pharmaceuticals' Shares Issued stood at $19000.0 in 2021, then surged by 2126.32% to $423000.0 in 2022, then plummeted by 89.83% to $43000.0 in 2023, then soared by 251.16% to $151000.0 in 2024, then surged by 266.23% to $553000.0 in 2025.
  • The last three reported values for Shares Issued were $553000.0 (Q4 2025), $653000.0 (Q3 2025), and $685000.0 (Q2 2025) per Business Quant data.